欧洲泌尿外科学会指南:肌层浸润性和转移性膀胱癌2023年指南摘要
本文概述了2023年欧洲泌尿外科学会(EAU)肌层浸润性和转移性膀胱癌(MMIBC)指南更新,涵盖诊断与治疗。证据检索截止至2022年5月4日,基于Medline、EMBASE和Cochrane图书馆的年度范围综述,对推荐意见赋予证据级别和推荐强度,提供基于证据的临床管理推荐和共识声明。
要点
- 膀胱MRI在疾病分期上优于CT,尤其区分T1与T2期,可能改变高危侵袭性肿瘤患者的治疗方式。
- 新辅助全身治疗仍以顺铂为基础;术后高危且未接受新辅助治疗者强烈推荐辅助化疗。
- 在经选择的男女患者中,保留性器官的膀胱切除术功能结局更好且不损害肿瘤学结局;机器人与开放膀胱切除术结局相当。
核心结论
- 该2023年EAU指南摘要提供了MMIBC诊断与治疗的最新信息,供纳入临床实践。
研究设计与样本
- 自2017年起每年对MMIBC指南所有领域进行广泛范围综述,检索Medline、EMBASE和Cochrane图书馆数据库用于年度指南更新。
- 对证据赋予证据级别和推荐强度,2023年MIBC指南的证据截止日期为2022年5月4日。
主要发现
- 应就膀胱癌危险因素对患者进行咨询,病理学家应详细描述肿瘤和淋巴结,包括组织学亚型的存在。
- 强调前列腺尿道是否存在尿路上皮癌(UC)的重要性;膀胱MRI在疾病分期上优于CT,尤其区分T1与T2期,可能改变高危侵袭性肿瘤患者的治疗方式。
- 上尿路、淋巴结和远处转移的影像学检查采用CT或MRI;氟脱氧葡萄糖正电子发射断层扫描/CT的附加价值仍需确定。
- 虚弱和合并症患者应由多学科团队评估;术后组织学仍是最重要的预后变量,循环肿瘤DNA似乎是令人感兴趣的预测标志物。
- 新辅助全身治疗仍以顺铂为基础;在有动力且经选择的男女患者中,保留性器官的膀胱切除术功能结局更好且不损害肿瘤学结局。
关键数值与推荐
- 机器人膀胱切除术与开放膀胱切除术结局相当,应联合(扩大)淋巴结清扫。
- 尿流改道类型在考虑患者和肿瘤特征后为个体化选择;根治性膀胱切除术仍是高度复杂的手术,并发症和死亡风险可观,但医院手术量较高(>20例/年)时观察到较低的发生率。
- 经适当患者选择,三模式治疗(放化疗)与根治性膀胱切除术结局相当。
- 术后辅助化疗改善高危且未接受新辅助治疗患者的疾病特异性生存和总生存(OS),强烈推荐。
- 对辅助纳武利尤单抗为弱推荐,因OS数据尚未获得。
临床怎么用
- 应使用经过验证的问卷在基线和治疗后评估健康相关生活质量。
- 需要监测以发现复发性癌症和功能结局;随访发现的复发似乎比症状性复发的预后更好。
局限性
- 氟脱氧葡萄糖正电子发射断层扫描/CT的附加价值仍需确定。
- 对辅助纳武利尤单抗为弱推荐,因OS数据尚未获得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: We present an overview of the updated 2023 European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). OBJECTIVE: To provide practical evidence-based recommendations and consensus statements on the clinical management of MMIBC with a focus on diagnosis and treatment. EVIDENCE ACQUISITION: A broad and comprehensive scoping exercise covering all areas of the MMIBC guidelines has been performed annually since 2017. Searches cover the Medline, EMBASE, and Cochrane Libraries databases for yearly guideline updates. A level of evidence and strength of recommendation are assigned. The evidence cutoff date for the 2023 MIBC guidelines was May 4, 2022. EVIDENCE SYNTHESIS: Patients should be counselled regarding risk factors for bladder cancer. Pathologists should describe tumour and lymph nodes in detail, including the presence of histological subtypes. The importance of the presence or absence of urothelial carcinoma (UC) in the prostatic urethra is emphasised. Magnetic resonance imaging (MRI) of the bladder is superior to computed tomography (CT) for disease staging, specifically in differentiating T1 from T2 disease, and may lead to a change in treatment approach in patients at high risk of an invasive tumour. Imaging of the upper urinary tract, lymph nodes, and distant metastasis is performed with CT or MRI; the additional value of flurodeoxyglucose positron emission tomography/CT still needs to be determined. Frail and comorbid patients should be evaluated by a multidisciplinary team. Postoperative histology remains the most important prognostic variable, while circulating tumour DNA appears to be an interesting predictive marker. Neoadjuvant systemic therapy remains cisplatin-based. In motivated and selected women and men, sexual organ-preserving cystectomy results in better functional outcomes without compromising oncological outcomes. Robotic and open cystectomy have comparable outcomes and should be combined with (extended) lymph node dissection. The diversion type is an individual choice after taking patient and tumour characteristics into account. Radical cystectomy remains a highly complex procedure with considerable morbidity and risk of mortality, although lower rates are observed for higher hospital volumes (>20 cases/yr). With proper patient selection, trimodal therapy (chemoradiation) has comparable outcomes to radical cystectomy. Adjuvant chemotherapy after surgery improves disease-specific survival and overall survival (OS) in patients with high-risk disease who did not receive neoadjuvant treatment, and is strongly recommended. There is a weak recommendation for adjuvant nivolumab, as OS data are not yet available. Health-related quality of life should be assessed using validated questionnaires at baseline and after treatment. Surveillance is needed to monitor for recurrent cancer and functional outcomes. Recurrences detected on follow-up seem to have better prognosis than symptomatic recurrences. CONCLUSIONS: This summary of the 2023 EAU guidelines provides updated information on the diagnosis and treatment of MMIBC for incorporation into clinical practice. PATIENT SUMMARY: The European Association of Urology guidelines panel on muscle-invasive and metastatic bladder cancer has released an updated version of the guideline containing information on diagnosis and treatment of this disease. Recommendations are based on studies published up to May 4, 2022. Surgical removal of the bladder and bladder preservation are discussed, as well as updates on the use of chemotherapy and immunotherapy in localised and metastatic disease.
引用
- Alfred Witjes J, Max Bruins H, Carrión A, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol. 2023. PMID: 37858453. doi:10.1016/j.eururo.2023.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。